Spirapril
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Spirapril hydrochloride (Renormax) is an ACE inhibitor antihypertensive drug used to treat hypertension. It belongs to dicarboxy group of ace inhibitor.
Like many ACE inhibitors, this is a prodrug which is converted to the active metabolite spiraprilat following oral administration. Unlike other members of the group, it is eliminated both by renal and hepatic routes which may allow for greater use in patients with renal impairment.[1] However data on its effect upon the renal function is conflicting.[2]
It is produced synthetically by combining the following two pharmaceutical intermediates:
(S)-1,4-Dithia-7-azaspiro(4,4)-nonane-8-carboxylic acid hydrobromide CAS 75776-79-3
and
N-[1-(S)-ethoxycarbonyl-3-phenylpropyl)-L-Alanine (ECPPA) [2]
Footnotes
- ↑ Shohat J, Wittenberg C, Erman A, Rosenfeld J, Boner G (1999). “Acute and chronic effects of spirapril, alone or in combination with isradipine on kidney function and blood pressure in patients with reduced kidney function and hypertension”. Scand J Urol Nephrol. 33 (1): 57&ndash, 62. doi:10.1080/003655999750016294. PMID 10100366.
- ↑ Noble S, Sorkin E (1995). “Spirapril. A preliminary review of its pharmacology and therapeutic efficacy in the treatment of hypertension”. Drugs. 49 (5): 750&ndash, 66. doi:10.2165/00003495-199549050-00008. PMID 7601014.
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH